The second COVID-19 pandemic year challenged the US Food and Drug Administration’s Office of Pharmaceutical Quality in new ways as it worked to complete increasingly complex chemistry, manufacturing and controls reviews while surveilling global manufacturing infrastructure despite lingering travel restrictions, OPQ director Michael Kopcha said in an interview as the office released its 2021 annual report.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?